FDA Issues New Anemia Drug Warnings

Law360, New York (March 12, 2007, 12:00 AM EDT) -- The U.S. Food and Drug Administration has revised the product labeling for a class of biotech drugs used to treat anemia, dealing a blow to drug maker Amgen.

The FDA issued a black box warning—its strongest—Friday for Aransep, Epogen and Procrit, all erythropoiesis-stimulating agents or ESAs. The agency said that physicians should monitor red blood cell levels and carefully weigh the risks of using the drugs against transfusion risks.

The FDA said that recently completed studies of the drugs describe an increased risk of death, blood...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.